8. Insmed Incorporated (NASDAQ:INSM)
Insmed Incorporated (NASDAQ: INSM) takes the No. 8 spot among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and the company’s story is one of the more dramatic names in this section because investor sentiment has recently shifted sharply. Trading at $103.38, with the stock down 1.04%, Insmed Incorporated (NASDAQ: INSM) is backed by 67 hedge fund holders and remains a closely watched biopharmaceutical stock focused on rare diseases and serious respiratory conditions. While Insmed Incorporated (NASDAQ: INSM) may not always be viewed in the same way as software-heavy AI healthcare companies, it remains relevant for investors watching innovative healthcare stocks, rare disease stocks, respiratory disease stocks, biotech stocks, and companies using advanced research and data-driven development to address difficult medical markets.
On June 15, Mizuho lowered its price target on Insmed Incorporated (NASDAQ: INSM) to $192 from $202, while maintaining an Outperform rating on the shares. That combination is important. The price target was reduced, but the bullish rating stayed in place, meaning the firm still sees substantial upside from current levels. Mizuho said the recent selloff created a buying opportunity, even though Insmed Incorporated (NASDAQ: INSM) shares had fallen 29% since the company’s first-quarter report. The firm described the sharp move in investor sentiment as “shocking” and expressed confidence in both Insmed Incorporated (NASDAQ: INSM) and BRINSUPRI. For investors, this is the classic biotech setup: the stock can be volatile, but analysts may still see major upside if the company’s pipeline and commercial execution remain on track.
The recent leadership update also adds to the story. On June 23, Insmed Incorporated (NASDAQ: INSM) announced the appointment of Samuele Butera as Senior Vice President and General Manager, Global Respiratory, effective immediately. He will lead the company’s Respiratory Therapeutic Area, report to Chair and CEO Will Lewis, and join the executive committee. Leadership appointments can sometimes look routine, but in biotech, they matter a lot when a company is preparing for major product launches, label expansions, or pipeline development. Will Lewis said Butera’s commercial leadership experience would support the launch of BRINSUPRI, the potential label expansion of ARIKAYCE, and the development of the TPIP program. That gives investors three specific areas to watch: BRINSUPRI commercialization, ARIKAYCE growth, and TPIP pipeline progress.
Butera called it “a defining moment” for Insmed Incorporated (NASDAQ: INSM), and that phrase is not just corporate language. Biopharmaceutical companies often go through defining moments when they transition from development stories into commercial execution stories. For Insmed Incorporated (NASDAQ: INSM), the next phase may depend heavily on whether the company can successfully advance BRINSUPRI, expand ARIKAYCE, and continue developing TPIP and other pipeline candidates. Investors following rare disease stocks know that a strong pipeline can create major long-term value, but execution risk is always present. Regulatory timelines, physician adoption, reimbursement, clinical data, and competitive dynamics can all affect the outcome.
Insmed Incorporated (NASDAQ: INSM) is a biopharmaceutical company that produces and markets medicines for rare diseases, with a focus on Brensocatib and Treprostinil Palmitil Inhalation Powder pipeline programs. For investors searching for best healthcare stocks, biotech stocks with upside, rare disease stocks, respiratory treatment stocks, and long-term medical innovation stocks, Insmed Incorporated (NASDAQ: INSM) deserves attention because the market appears divided between recent selling pressure and analyst confidence. If Mizuho’s view proves right and the selloff was overdone, Insmed Incorporated (NASDAQ: INSM) could remain one of the more interesting healthcare names in this ranking.
Click next to see the following stock...
